Dr. Reddy’s Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 80574.04 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 5053.00 Crore, up 4.17 % from last quarter Total Income of Rs 4850.80 Crore and up 11.95 % from last year same quarter Total Income of Rs 4513.60 Crore. Company reported net profit after tax of Rs 363.80 Crore in latest quarter.
Investment Rationale
The brokerage values DRRD’s base business EPS of INR195 at a 12M forward P/E multiple of 25x and add INR260 per share of NPV from the g-Revlimid opportunity. Accordingly, it arrives at TP of INR5,200 on a 12M forward earnings basis. It maintains Neutral on a limited upside from current levels.
Promoter/FII Holdings
Promoters held 26.7 per cent stake in the company as of June 30, 2021, while FIIs held 29.4 per cent, DIIs 15.7 per cent and public and others 28.2 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
